Jan Davis
Impact in
- Hematology top 1%
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Chronic Myeloid Leukemia Treatments
- Genetics top 5%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
-
- Acute Myeloid Leukemia Research 6
- Chronic Myeloid Leukemia Treatments 1
-
- Histone Deacetylase Inhibitors Research 2
- Epigenetics and DNA Methylation 1
- Co-authors
- Hagop M. Kantarjian (7 shared papers)Guillermo Garcia‐Manero (6 shared papers)Susan O’Brien (6 shared papers)Francis J. Giles (6 shared papers)Jörge E. Cortes (4 shared papers)Jean‐Pierre J. Issa (5 shared papers)Stefan Faderl (3 shared papers)William G. Wierda (2 shared papers)
- Journals
- Blood (5 papers)Journal of Clinical Oncology (1 paper)PubMed (1 paper)
- Partner nations
- United States
In The Last Decade
Jan Davis
7 papers receiving 804 citations
Jan Davis's Hit Papers
Peers
Comparison fields: 5 of 46
- Hematology 595
- Genetics 161
- Public Health, Environmental and Occupational Health 184
- Molecular Biology 371
- Oncology 63
Countries citing papers authored by Jan Davis
This map shows the geographic impact of Jan Davis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Davis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Davis more than expected).
Fields of papers citing papers by Jan Davis
This network shows the impact of papers produced by Jan Davis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Davis. The network helps show where Jan Davis may publish in the future.
Co-authors
The 25 scholars most cited alongside Jan Davis, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia Hit paper breakdown → | 2006 | 517 |
| 2 | 2003 | 242 | |
| 3 | 2005 | 24 | |
| 4 | 2004 | 18 | |
| 5 | 2005 | 8 | |
| 6 | A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes. | 2002 | 8 |
| 7 | 2005 | 4 |
About Jan Davis
Jan Davis is a scholar working on Hematology, Molecular Biology, Genetics, Oncology and Epidemiology, having authored 7 papers that have together received 821 indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (6 papers), Pneumocystis jirovecii pneumonia detection and treatment (2 papers), Histone Deacetylase Inhibitors Research (2 papers), Neutropenia and Cancer Infections (2 papers), Chronic Myeloid Leukemia Treatments (1 paper), Epigenetics and DNA Methylation (1 paper), Chronic Lymphocytic Leukemia Research (1 paper) and Acute Lymphoblastic Leukemia research (1 paper). The work is most often cited by research in Hematology (595 citations), Genetics (161 citations), Public Health, Environmental and Occupational Health (184 citations), Molecular Biology (371 citations) and Oncology (63 citations). Jan Davis has collaborated with scholars based in United States. Frequent co-authors include Hagop M. Kantarjian, Guillermo Garcia‐Manero, Susan O’Brien, Francis J. Giles, Jörge E. Cortes, Jean‐Pierre J. Issa, Stefan Faderl, William G. Wierda, Alessandra Ferrajoli and Farhad Ravandi. Their work appears in journals such as Blood, Journal of Clinical Oncology and PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.